Loading clinical trials...

One Research on Improving Cognitive Impairment Caused by Hypertension | Clinical Trials | Clareo Health

UNKNOWN

One Research on Improving Cognitive Impairment Caused by Hypertension

One Research on Application of Key Technologies About Improving Cognitive Impairment Caused by Hypertension With the Therapy of Early Intervention With Qianyang Yuyin Granules

NCT03943420•Jiangsu Famous Medical Technology Co., Ltd.

View on ClinicalTrials.gov

Summary

Using the therapy of early intervention with Qianyang Yuyin Granules to improve cognitive impairment caused by hypertension.

Detailed Description

Using the therapy of early intervention with Qianyang Yuyin Granules to improve cognitive impairment caused by hypertension. The investigators designed a multi-center randomized controlled clinical trial to study the security and effectiveness of this therapy.

Eligibility

Age

55 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Aged 55 to 75 years old, male or female;
•Having a history of hypertension for more than 2 years but can maintain SBP ≤ 140 mmHg and BDP ≤ 90 mmHg with medication；
•21 ≤ MMSE \< 26, or 14 ≤ MoCA \< 26, CDR \< 0.5. Bseides, the chief complaint must happen after having hypertension；
•Meet TCM Syndrome Differentiation Standard：according to the Guidelines for the Clinical Research of Chinese Medicine New Drugs ( published by China Medical Science Press ) ：Overabundant liver-fire type：dizziness and headache, both face and eyes are red, dry mouth and bitter taste in mouth, red tongue with yellowish coating, wire and frequent pulse. Yin deficiency and yang hyperactivity type: dizziness and headache, Tinnitus and forgetfulness, sphoria with feverish sensation in chest \& palms \& soles, palpitation and insomnia, red tongue \& thin white or less coating, wiry weak and numbered pulse；
•CTMRI hint: leukoaraiosis and no sign of Cerebral infarction；
•Patients or the guardian hold the right opinions over the research and are willing to obey researcher's orders；
•Having a certain degree of education (being able to read simple newspapers in the past)；
•Patients agree to sign informed consent。

Exclusion Criteria

•Secondary hypertension；
•Taking certain kinds of antihypertensive drugs which may damage brain cognitive function；
•Diagnosed as depression or other mental disorders according to DSM-IV；
•Diagnosed as vascular dementia according to diagnostic criteria, CDR ≥ 0.5; alzheimer disease or dementia caused by some other reasons (including mixed dementia according to diagnostic criteria for VCI); cognitive impairment due to head injury。
•Suffering from certain kinds of diseases which may interfere the assessment of cognitive function, including those who are diagnosed as alcoholics and drugs or psychotropic medicine abusers during the last 5 years according to DSM-IV；
•Accompanied with severe neurological function disorder；
•Asthma, chronic severe primary cardiovascular disease, liver lesion, hematological lesions, lung diseases, diabetes or other severe diseases may influence the patients' survival such as cancer or AIDS；
•Other: Such as poor compliance, or can not attend the follow-up visit in time for some reasons；
•Taking the same kind of medicine during the last 30 days which may influence the trial；
•Is participating in another clinical study；
+1 more criteria

Locations (1)

Jiangsu Province Hospital of Chinese Medcine

Nanjing, Jiangsu, China

Key Dates

Start Date

December 28, 2018

Primary Completion Date

December 1, 2020

Completion Date

December 1, 2020

Last Updated

May 9, 2019

Enrollment

144

ESTIMATED participants

Conditions

Hypertension

Contacts

Cheng Chang, PhD

CONTACT

+8613851821996 chch1967@163.com

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

RECRUITINGPHASE2

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820

Pulmonary Hypertension

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 9, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

One Research on Improving Cognitive Impairment Caused by Hypertension

Inclusion Criteria

Exclusion Criteria

Natural History of Noncirrhotic Portal Hypertension

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Penn Medicine Healthy Heart

Preliminary Human Trials of F230 Tablets